Combining Tunlametinib and Vemurafenib for Advanced Colorectal Cancer

A Multicenter, Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

This study is testing if combining two drugs, Tunlametinib and Vemurafenib, can help people with advanced colorectal cancer that has a specific mutation do better than standard chemotherapy.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 165 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Shanghai Kechow Pharma, Inc. (Industry-sponsored)
• Drugs / interventions: Tunlamatinib, Chemotherapy
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06008119 on ClinicalTrials.gov

What this trial studies

This multicenter, randomized, open-label Phase 3 study evaluates the efficacy and safety of Tunlametinib combined with Vemurafenib in patients with BRAFV600E mutant metastatic colorectal cancer. Participants will be compared against those receiving standard chemotherapy treatments after their disease has progressed following previous therapies. The study aims to determine if this combination therapy can provide better outcomes than traditional chemotherapy options. Patients will be monitored for disease progression and treatment-related side effects throughout the trial.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 70 with confirmed BRAFV600E mutant metastatic colorectal cancer who have experienced disease progression after prior treatments.

Not a fit: Patients without the BRAFV600E mutation or those who have not progressed after previous therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new effective option for patients with a specific genetic mutation in metastatic colorectal cancer.

How similar studies have performed: Other studies have shown promising results with targeted therapies in similar patient populations, suggesting potential for success with this approach.

Eligibility criteria

Inclusion Criteria:

* Inclusion Criteria:

  1. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures.
  2. Male or female patients with 18 to 70 years of age at time of informed consent;
  3. Histological or cytologically confirmed metastatic CRC
  4. Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory (BRAFV600 is permitted)
  5. Able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archival or newly obtained) for confirmatory central laboratory testing of BRAF mutation status.
  6. Progression of disease after 1 or more prior regimens in the metastatic setting
  7. At least 1 site of radiographically measurable disease by RECIST 1.1
  8. Eastern Cooperative Oncology Group (ECOG) Performance Status(PS) of 0 to 1;
  9. Life expectancy ≥ 3 months;
  10. Can swallow the medicine,
  11. Adequate hematologic, renal, cardiac and liver function as defined by laboratory values performed within 7 days prior to initiation of dosing:
  12. Be willing and able to complete all the study procedures and follow-up examinations.

Exclusion Criteria:

* Exclusion Criteria:

  1. Prior treatment with any BRAF and MEK inhibitor;
  2. Known contraindication to receive the treatment of control arm (according to latest PI).
  3. Symptomatic brain metastasis or leptomeningeal disease
  4. History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization
  5. Known history of acute or chronic pancreatitis
  6. Uncontrolled GI bleeding, Dysphagia，refractory nausea, vomiting, small bowel resection or any other gastrointestinal ailment that would preclude study drug absorption.
  7. Serious cardiovascular disease , including uncontrolled congestive heart failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and severe cardiac arrhythmia , deep vein thrombosis or pulmonary emboli or cerebrovascular events ≤ 6 months prior to starting study treatment;
  8. History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
  9. Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
  10. Uncontrolled blood pressure despite medical treatment
  11. Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
  12. Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy
  13. Anti-HIV(+) , Anti-TP( +); Active hepatitis B or hepatitis C infection …….

Where this trial is running

Beijing, Beijing Municipality

• Beijing Oncology Hospital — Beijing, Beijing Municipality, China (Recruiting)

Conditions Colorectal Cancer Metastatic; BRAFV600E mutant